An Analysis Finds Shingrix is Highly Effective for Preventing Shingles in Seniors
A real-world analysis shows Shingrix effectively prevents shingles in adults over the age of 65, including immunocompromised people.
Shingles is a viral infection that occurs when the varicella-zoster virus (VZV) reactivates in the body, presenting as a rash with painful blisters.
According to the CDC, shingles is more common in adults over 50, with 5-30% of patients experiencing post-herpetic neuralgia (PHN), a long-lasting nerve pain.
Two doses of Shingrix provide better protection than one, making it effective in preventing shingles in adults over 65, including immunocompromised adults.
Shingrix is a recombinant zoster vaccine (RZV) manufactured by GSK, and its effectiveness was published in the Annals of Internal Medicine.
Author's summary: Shingrix prevents shingles in seniors.